Abbonarsi

Preference, adherence, and acceptability of 3 nonmedicated intravaginal rings of differing external diameters: a randomized, crossover trial - 22/08/25

Doi : 10.1016/j.ajog.2025.03.001 
Barbara A. Friedland, MPH a, , Jessica M. Sales, PHD b, Jessica Atrio, MD c, Marlena G. Plagianos, MS a, J. Brady Burnett-Zieman, MPH a, Shakti Shetty, MPH b, Nicole Roselli, MD c, d, Renee Rolston, MD c, e, Ann Gottert, PHD f, Karina Avila, MPH c, Irene V. Bruce, MPH a, Caio Sant'Anna Marinho, MD c, Michelle Nguyen, MPH b, Ruth Merkatz, PHD a, Lisa B. Haddad, MD a
a Population Council, Center for Biomedical Research, New York, NY 
b Rollins School of Public Health, Emory University, Atlanta, GA 
c Albert Einstein College of Medicine, Bronx, NY 
d Division of Female Pelvic Medicine and Reconstructive Surgery, Bellevue Hospital/NYU Langone Medical Center, New York, NY 
e Urogynecology and reconstructive pelvic surgery, Department of Obstetrics and Gynecology, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 
f Population Council, Social and Behavioral Sciences Research, Washington, DC 

Corresponding author: Barbara A. Friedland, MPH.

Abstract

Background

No empirical data support the 54 to 58 mm external diameter of intravaginal rings currently available and in development for contraception and other indications. Understanding how external diameter affects preference, adherence, and acceptability is critical for optimizing future product development.

Objective

Our primary objectives were to determine which of 3 nonmedicated rings of differing external diameters was preferred and yielded the highest adherence. Secondary objectives were comparing acceptability, patterns of adherence, and safety of the 3 rings.

Study Design

In an open-label, 3-way crossover trial, healthy, HIV-uninfected, monogamous, sexually active, nonpregnant, 18-year-old to 40-year-old cisgender women and their male partners in Atlanta, GA and the Bronx, NY were randomly assigned to the sequence of using 3 nonmedicated silicone rings (46 mm, 56 mm, and 66 mm external diameters) continuously for approximately 30 days each (90 days total; November 2021 to December 2022). We tested whether end-of-study preference for any of the 3 rings was greater than 0.33 (binomial proportion, exact test). We used mixed-effect regression models with random intercepts by participants to compare adherence (ring never out for more than 30 minutes in 24 hours) and probability of removals (including reasons for removal), expulsions, and the ring being out of the vagina all day, per ring, per day of use with the 56-mm ring as the reference group and to compare scores on a novel 19-item acceptability scale with items related to ease and experience of use and impact on sex.

Results

Of 24 women, 23 completed the study (median age: 26.7 years [standard deviation: 3.78]). Most were college graduates (92%), White (63%), non-Hispanic (79%), single (79%), and nulliparous (92%). At the end of the study, 59% preferred the smallest (46 mm) ring versus 18% each for the 56-mm and 66-mm rings ( P =.0045). The proportion of participants who were adherent did not differ by ring (46 mm, 78%; 56 mm, 75%; 66 mm, 59%; P =.30); however, odds of expulsion were higher for the 46-mm (odds ratio: 5.72; 95% confidence interval: 1.25–26.1) and 66-mm (odds ratio: 25.9; 95% confidence interval: 6.11–109) rings than for the 56-mm ring. The 66-mm ring also had greater odds of being out (removal or expulsion, any length of time) than the 56-mm ring (odds ratio: 6.50; 95% confidence interval: 3.46–12.2).

Mean acceptability scale scores were identical (4.54/5) for the 46-mm and 56-mm (smallest and medium) rings and significantly higher than for the largest, 66-mm ring (3.94/5; P < .001).

Conclusion

Although the 46-mm ring was preferred by more women and had higher rates of adherence compared to the other 2 rings, the 56-mm ring was rated as equally acceptable with significantly fewer reports of expulsions/removals compared to the other 2 rings. These data confirm that the current 54 to 58 mm diameter of vaginal rings on the market and in development is acceptable and performs well. Future studies should explore the effect of other mechanical attributes, such as compressibility, on preference, adherence, and acceptability, as well as investigating ring characteristics in other populations.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 The authors report no conflicts of interest.
  Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health under award number R01AI150360 .
 The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
 Date of registration: October 20, 2021.
 Date of initial participant enrollment: January 20, 2022.
  Clinical trial identification number: Clinicaltrials.gov NCT05128136.
  URL of registration site: NCT05128136?intr=non-medicated%20silicone%20ring&rank=2
  All data and supporting documents, including the protocol, statistical analysis plan, and data collection instruments are available via the Population Council Dataverse ( QFDTPP ).
 Some of the data were included in an oral presentation at the 18th International Conference on Treatment and Prevention Adherence, Puerto Rico, June 11–13, 2023, and at the 2023 National Contraception Meeting, Houston, TX, November 13–16, 2023.
  Trial Registration: Clinical Trials.gov: NCT05128136. NCT05128136?intr=non-medicated%20silicone%20ring&rank=2
  Cite this article as: Friedland BA, Sales JM, Atrio J, et al. Preference, adherence, and acceptability of 3 nonmedicated intravaginal rings of differing external diameters: a randomized, crossover trial. Am J Obstet Gynecol 2025;233:188.e1-10.


© 2025  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 233 - N° 3

P. 188.e1-188.e10 - settembre 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Delay to timely treatment in locally advanced cervical cancer: insurance inequities in access to gynecologic oncology
  • Jessica Liang, Audrey Mvemba, Megan Swanson, I-Chow (Joe) Hsu, Edwin Alvarez, Jocelyn Chapman, Katherine Fuh, Lee-may Chen, Stephanie Cham
| Articolo seguente Articolo seguente
  • Universal screening and valacyclovir for first trimester primary cytomegalovirus: a cost-effectiveness analysis
  • Sarah K. Dzubay, Amelia H. Gagliuso, Megha Arora, Uma Doshi, Aaron B. Caughey

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.